TheranosticTrials.org

Clinical Trial · NCT04276597

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Overview

Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET. The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.

Sponsor

Excel Diagnostics and Nuclear Oncology Center

Phase

Phase 2

Contacts

Ebrahim Delpassand, MD (PRINCIPAL_INVESTIGATOR)

Afshin Shafie, MD (STUDY_DIRECTOR)

Rodolfo Nunez, MD (STUDY_DIRECTOR)

Ayman Gaber, MD (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT04276597

Drug / Compound

DOTATOC

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • ECOG status 0-2.
  • All available FDA-approved therapies for which the subject is eligible have been exhausted (with the exception of PRRT), unless available therapies are refused by the subject (with the exception of somatostatin analogue, octreotide, and somatuline).
  • Bilirubin: ≤3 times ULN
  • Somatostatin receptor positive (SSTR+) disease, as evidenced by available FDA, commercially of IND approved SSTR imaging (SRI), within 4 weeks prior to the first cycle
  • Serum creatinine ≤ 150 µmol/liter or 1.7 mg/dl
  • Recent blood test results (within 2weeks pre-dose) as follows:
  • Appropriate diagnostic imaging studies, at the discretion of the P.I. including but not limited to CT, MRI , 18F-FDG PET/CT, NAF PET/CT bone scan, ultrasound, etc. of the tumor region or suspected area within the 4 weeks of dosing day.
  • Measurable disease per RECIST 1.1, on CT/MRI scans, defined as at least 1 lesion with ≥ 1 cm in longest diameter (lymph nodes along short axis \>15 mm).
  • Histologically/cytologically confirmed diagnosis of SSTR (+) neuroendocrine tumors of the lung, Pheochromocytoma, Paraganglioma, thymus, and unknown primary, unresectable or metastatic.
  • Sufficient bone marrow capacity as defined by WBC ≥2,500/µl and WBC≥2,000/mm3 for subsequent cycles; platelets ≥ 100,000 (100 \* 103/mm3) for the first treatment and ≥75,000 for the subsequent therapies, Hgb ≥8.9 g/dl for the first treatment and 8.0 g/dl for the subsequent therapies, ANC ≥1500/mm3 for the first treatment and ≥1000/ mm3; for the subsequent therapies.
  • Serum albumin \> 3.0g/L (\<3 g/L may be acceptable at the discretion of investigator, if PT, PTT, and INR are within normal range)
  • Life-expectancy of at least 12 weeks.
  • ALT, AST values ≤3 times ULN
  • Negative pregnancy test in women capable of child-bearing within 48 hours of IMP administration.

Exclusion

  • Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.
  • Subjects with unusual hematological parameters, including an increased MCV (\>105fL), and especially in those who had previous chemotherapy, the advice of a hematologist should be sought for adequate further work-up
  • Glomerular Filtration Rate (GFR) \< 35 mL/min
  • Any subject who is taking concomitant medications that decrease renal function (such as aminoglycoside antibiotics).
  • Planned (for the period of study participation): chemotherapy, immunotherapy, radiation therapy (unless regional for pain relief) chemo-embolization, bland embolization, radio-embolization, treatment with cyclosporine-A.
  • Subjects with prior peptide receptor radionuclide therapy (PPRT).
  • Uncontrolled congestive heart failure; subjects suspected of having this condition need to show ejection fraction of \> 35% as determined by MUGA scan.
  • Completion of: (1) cytotoxic chemotherapy for less than 6 weeks; (2) a biological agent for less than 5 half-lives; and (3) radiation therapy (except regional for pain relief) for less than 6 weeks prior to study enrolment,
  • Known brain metastases; unless these metastases have been treated and stabilized 6 months prior to enrolment
  • Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to treatment.
  • Female subjects who are pregnant, lactating or women of childbearing potential not willing to practice effective contraceptive techniques during the study period and for 67 days (more than 10 half-lives of 177Lu after the last treatment, or male subjects who have female partners of childbearing potential not willing to practice abstinence or effective contraception, during the study period and for 67 days after the last treatment.
  • Indication for surgical lesion removal with curative potential
  • Known hypersensitivity to any of the excipients of Lu-177 DOTATOC.